From microbiome signatures to precision oncology in colorectal cancer

Over the past decade, the gut microbiome has evolved from a promising area of investigation to one of the most compelling biological dimensions of colorectal cancer (CRC). [1][2] Numerous studies have consistently identified microbial dysbiosis in patients with CRC, with recurrent enrichment of oral-associated species such as Fusobacterium nucleatum, Parvimonas micra, and Peptostreptococcus stomatis. [3][4][5] These observations have fueled growing interest in the microbiome as a source of non-invasive biomarkers and a potential therapeutic target. Yet one fundamental question has persisted: are these microbial signatures sufficiently robust and reproducible to support clinical translation?The large international metagenomic analysis by Piccinno and colleagues [6] provides one of the strongest answers to date. By integrating 3,741 stool metagenomes from 18 independent cohorts across 11 countries, the authors demonstrate that microbiome-based classification of CRC is remarkably reproducible across diverse populations while simultaneously revealing biologically meaningful heterogeneity. Beyond confirming previously recognized CRC-associated taxa, the study incorporates stage-specific analyses, tumor location, and strain-level resolution, highlighting the complexity of host-microbe interactions and the importance of moving beyond species-level descriptions.The significance of this work extends beyond the identification of additional microbial biomarkers. Rather, it marks an important turning point for the field. For years, CRC microbiome research has been challenged by concerns regarding cohort-specific effects, methodological variability, and inconsistent reproducibility. By demonstrating that a core microbial signal persists across thousands of individuals, Piccinno and colleagues largely settle the debate over whether a reproducible CRC-associated microbiome exists. The question is therefore no longer whether a CRC-associated microbiome exists, but how these microbial signatures can be translated into mechanistic insights capable of informing precision oncology. This transition-from microbial discovery to microbial interventionis likely to define the next phase of cancer microbiome research, in which microbial communities evolve from disease biomarkers into biological targets and potentially programmable therapeutic tools. The conceptual evolution discussed throughout this article is summarized in Figure 1.One of the most important contributions of the study by Piccinno and colleagues [6] is not simply the confirmation of previously described CRC-associated microorganisms, but the demonstration that biologically relevant information lies beyond conventional taxonomic profiling. While Fusobacterium nucleatum has become the emblematic microbial biomarker of colorectal cancer [4,5,7], the present work highlights a more complex microbial ecosystem characterized by oral-derived communities, strain-level diversity, and contextdependent microbial interactions. [6] This shift challenges the long-standing tendency to interpret individual bacterial species as isolated biomarkers and instead encourages a more ecological view of the tumor microbiome.The incorporation of strain-resolved metagenomics represents a particularly significant advance. [6] Bacterial species encompass substantial genomic and functional heterogeneity, with individual strains differing in virulence factors, metabolic capabilities, immune-modulating properties, and colonization potential. [7,8] Consequently, assigning biological significance at the species level may obscure clinically relevant variation. The identification of distinct Fusobacterium clades and previously uncharacterized microbial genomes associated with colorectal cancer suggests that microbial functionality, rather than taxonomy alone, is likely to determine disease-associated phenotypes. [6] Equally important is the recognition that microbial signatures should be interpreted within the context of the host. Tumor location, disease stage, immune status, metabolic conditions, and environmental exposures all contribute to shaping the intestinal ecosystem and may influence both microbial composition and function. [6,9] Rather than merely representing biological variability, this heterogeneity may explain why similar microbial taxa display different clinical associations across individual patients. Future investigations should therefore move beyond cataloguing microorganisms toward integrating microbial genomic features with host molecular characteristics, immune landscapes, and tumor biology. [9,10] This systems-level perspective is particularly relevant for translational oncology.Understanding not only which microorganisms are present, but also how they interact with the host and with one another, will be essential for developing reliable biomarkers and identifying microbial targets suitable for therapeutic manipulation. [8][9][10] As the field progresses, functional microbiomics, multi-omics integration, and computational modeling are likely to become indispensable tools for transforming descriptive microbial signatures into clinically actionable biological knowledge. [6,9,10] The transition from microbiome discovery to clinical implementation represents one of the most exciting challenges in contemporary oncology. While the identification of reproducible microbial biomarkers is an essential first step, the goal extends far beyond diagnosis. A detailed understanding of microbial ecology, functional genomics, and hostmicrobe interactions are expected to provide the biological foundation for the development of innovative therapeutic strategies capable of modulating the tumor microenvironment. [5][6][7][8][9][10] In this context, studies such as that of Piccinno and colleagues have implications that reach well beyond colorectal cancer screening. By identifying reproducible microbial communities, strain-specific associations, and ecological patterns linked to disease